Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020

OBJECTIVES: To evaluate the incremental value of new drugs across disease areas receiving favourable coverage decisions by the UK’s National Institute for Health and Care Excellence (NICE) over the past decade. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study assessed favourable apprais...

Descripción completa

Detalles Bibliográficos
Autores principales: Polak, Tobias B, Cucchi, David GJ, Darrow, Jonathan J, Versteegh, Matthijs M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Health Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996039/
https://www.ncbi.nlm.nih.gov/pubmed/35396306
http://dx.doi.org/10.1136/bmjopen-2021-058279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996039/
https://www.ncbi.nlm.nih.gov/pubmed/35396306
http://dx.doi.org/10.1136/bmjopen-2021-058279

Ejemplares similares